Eli Lilly and QurAlis Forge New Path with ALS Drug Deal
Eli Lilly has taken a significant step in the battle against amyotrophic lateral sclerosis (ALS) through a promising partnership with QurAlis, a biotech firm based in Cambridge, Massachusetts. The deal, announced on Monday, underscores Lilly’s commitment to addressing neurodegenerative diseases despite the numerous challenges faced in this domain.
QurAlis, known for its innovative approaches to treating neurodegenerative disorders, has licensed its experimental ALS and frontotemporal dementia drug, QRL-204, to Eli Lilly. This move comes with an upfront payment of $45 million to QurAlis, and potential milestone payments that could reach up to $577 million. This partnership not only aims to advance QRL-204 but also includes collaborative efforts to develop other similar therapies.
Eli Lilly has long prioritized brain health, even as many pharmaceutical giants have scaled back their investments in this area due to frequent setbacks. The Indianapolis-based company is on the brink of obtaining approval for a new Alzheimer’s drug and has several other neurodegenerative disease treatments in various stages of clinical testing. This partnership with QurAlis aligns with Lilly’s broader strategy to maintain a strong presence in the neuroscience sector.
Related: Eli Lilly’s Weekly Insulin Injection As Effective As Daily Doses
Reversal and Renewal of Partnership
The collaboration between Lilly and QurAlis marks a notable reversal of their previous relationship. In 2020, QurAlis gained access to small molecule prospects for ALS and other brain diseases through an alliance with Lilly. Now, the roles have reversed as QurAlis hands over rights to an RNA-based therapy for ALS, known as QRL-204.
ALS, often referred to as Lou Gehrig’s disease, is a devastating condition that affects approximately 30,000 people in the United States. It is characterized by the progressive degeneration of motor neurons, leading to severe muscle weakness and eventual paralysis. Despite extensive research, there is currently no cure for ALS. Existing treatments offer only limited relief, and many experimental drugs have failed in clinical trials. The recent withdrawal of Amylyx Pharmaceuticals’ Relyvrio, due to a failed confirmatory trial, highlights the difficulties faced in developing effective treatments for ALS.
The Promise of QRL-204
QRL-204, the drug at the heart of this new deal, is designed to address faulty RNA processing in the UNC13A gene, a common mutation found in individuals with ALS and frontotemporal dementia. By correcting these errors with an antisense oligonucleotide approach, QurAlis aims to restore normal protein production and improve the functioning of nerve cell junctions. This innovative strategy holds promise for making significant advancements in the treatment of neurodegenerative diseases.
Andrew Adams, head of Lilly’s Institute for Genetic Medicine, expressed optimism about the potential impact of QRL-204. “This approach holds promise for delivering meaningful advances against a range of neurodegenerative diseases,” he said. In addition to advancing QRL-204, Lilly plans to work closely with QurAlis to identify other antisense oligonucleotides that target the UNC13A gene.
Broader Implications and Future Prospects
QurAlis is actively developing three other programs targeting ALS, frontotemporal dementia, and primary lateral sclerosis, a slower-progressing neurological disease affecting the upper body. Two of these programs are already in clinical testing, including another RNA-based therapy targeting a different ALS-associated gene. QRL-204, however, has emerged as a frontrunner in QurAlis’ pipeline.
Kasper Roet, CEO and co-founder of QurAlis, emphasized the importance of the partnership with Lilly. “We want to make sure that [QRL-204], which we are really excited about, gets the attention that it deserves,” he stated. The funds from the Lilly deal, along with an $88 million Series B round raised by QurAlis in 2023, will be instrumental in supporting clinical trials for the company’s other programs and expanding its workforce.
Related: Eli Lilly’s blockbuster obesity drug
A New Chapter in ALS Treatment
The partnership between Eli Lilly and QurAlis represents a beacon of hope for those affected by ALS and other neurodegenerative diseases. With significant financial backing and a collaborative approach, the two companies are well-positioned to make groundbreaking strides in this challenging field. The development of QRL-204, along with the identification of other potential therapies, could mark a new chapter in the fight against these debilitating conditions.
As the scientific community continues to seek effective treatments for ALS, the collaboration between established pharmaceutical leaders like Eli Lilly and innovative biotech firms like QurAlis demonstrates the power of combining resources and expertise. Together, they aim to push the boundaries of what is possible in the treatment of neurodegenerative diseases, offering renewed hope to patients and their families worldwide.
This latest deal not only reinforces Eli Lilly’s commitment to neurological research but also highlights the critical role of biotech startups in advancing medical science. As research progresses, the partnership between Lilly and QurAlis could pave the way for new, life-changing therapies that address the urgent unmet needs of those living with ALS and other neurodegenerative disorders.
Read: A list of the top 50 pharmaceutical companies in the word.